Welcome to EVolution Therapeutics
EVs are novel candidates for the delivery of bio-active molecules with their high bioavailability, intrinsic capability to cross biological barriers and remarkable biocompatibility.
Our cutting-edge research has the potential to develop the next generation of therapeutics. By leveraging our expertise in the field of EVs, we hope to translate our research into EV-based therapeutics for the treatment of inflammatory diseases. It is only in recent years, that scientists have had the tools to begin to understand the bio-functionality of EVs. We hope to position ourselves at the forefront of this therapeutic revolution.
Unrestrained inflammation acts as a key driver of many significant diseases including cancer, cardiovascular disease, chronic inflammation and poor wound healing. The therapeutic armamentarium for inflammatory diseases is currently limited in scope and our hope is to create a new therapeutic avenue with our novel innovation.
Dr James Gavin’s enthusiasm for research into disease model systems grew while undertaking a PhD at Aston University. The PhD addressed inflammation in Cystic Fibrosis, with a focus on the role of EVs. This provided Dr Gavin the foundational basis to learn a broad range of techniques, which centred on the bio-functional analysis of EVs. From there he transitioned into a post-doctoral position in Professor Devitt’s group, investigating the ‘active EV’ and its role in the control of inflammation, alongside development of bioengineered EVs for therapeutic application.
Professor Andrew Devitt is an inflammatory cell biologist whose early work highlighted the importance of the innate immune system in dying (apoptotic) cell removal. His group at Aston University studies the molecular mechanisms by which apoptotic cells and immune cells communicate through the use of EVs and interact to mediate immune cell responses.
Together Dr James Gavin and Professor Andrew Devitt have formed EVolution Therapeutics. Our hope is the development of EV based therapies within the field of inflammatory disease, to create a paradigm shift away from passive disease management and towards active disease treatment.
If you want to know more about our work, please get in contact and we’ll be happy chat.